Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (A...
Brand Name : APT-1011
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2020
LOOKING FOR A SUPPLIER?